Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.
about
Membrane binding and bending in Ebola VP40 assembly and egressAnimal models for Ebola and Marburg virus infectionsAssembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tailsViral hemorrhagic fevers: advancing the level of treatmentCurrent ebola vaccinesThe 2014–2015 Ebola outbreak in West Africa: Hands OnSustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAbEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentTransmission of Ebola virus from pigs to non-human primatesDelayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesEbola haemorrhagic feverMonitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in LiberiaEbola virus disease and critical illness.Lipid nanoparticles for targeted siRNA delivery - going from bench to bedsideFiloviruses: One of These Things is (not) Like the OtherAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksPre-symptomatic diagnosis and treatment of filovirus diseasesLipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectivesStandardization of the filovirus plaque assay for use in preclinical studiesMouse models for filovirus infectionsZikaVR: An Integrated Zika Virus Resource for Genomics, Proteomics, Phylogenetic and Therapeutic AnalysisStructure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2.Development of RNA Aptamers Targeting Ebola Virus VP35Knocking down disease: a progress report on siRNA therapeuticsCurrent prospects for RNA interference-based therapiesProgress toward in vivo use of siRNAs-IIRescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNAPreparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught UsExperimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical TrialLipid-based vectors for siRNA deliveryEbola virus disease: What clinicians in the United States need to know.Updates in diagnosis and management of Ebola hemorrhagic fever.Monoclonal antibodies for the treatment of Ebola virus disease.Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.Could the Ebola virus matrix protein VP40 be a drug target?CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.Possible leap ahead in filovirus therapeutics.
P2860
Q21131091-ABA1F379-8D93-4597-AE99-BC09547FFD52Q21131118-7FA12C2C-69B3-4186-9A93-F1EE20ED165CQ21134356-D57DF884-7CCB-46BF-8528-BA4FF6E56E01Q21245298-A6BCE8F1-8F35-4DA8-A377-933FED6A38BEQ21534720-5856176C-C1C0-4320-906C-5F7288239CE6Q24049114-B201F999-5617-4173-836E-79EB9BB992BAQ24594601-CC896682-D1DE-421E-9BC4-51B522E61193Q24597625-D70353D1-670D-4E7A-BD1B-C6E47FDC6CFFQ24612028-37777BC8-F0E1-4E4C-8563-7B60712AB3FEQ24612811-852CE49C-7E80-4462-84D6-EB09939CBFA1Q24629338-E568EAEA-3F9C-4723-AEE3-00C0EA037792Q24696012-07FBE52D-E786-455C-931B-0A821F8D2C63Q26250274-B34DAD65-C640-45B0-BDA7-7F66A79F5715Q26741449-A6E60199-F9E6-4FBC-8965-EECA47A71B56Q26783063-9212684E-E1D1-46A3-85BA-00320C8501FEQ26801423-357FB066-3ED3-4C62-85AB-97EA23F4E2A1Q26823831-13C5CFE6-2632-4D7C-BA1E-5E9196F0ED65Q26859021-4A46CADC-49C3-40C8-A4D8-BAE9DCC3CF69Q27000207-1AD7CBAB-1B00-406E-A395-2433204E6923Q27011569-D809EE4B-166A-49CC-B3A2-04588BE85276Q27468686-88F7F7A1-1B68-4949-9FCA-AA3F7D383373Q27670489-F14E2FB3-0D8B-4C21-A13E-CEAD8940B8A2Q27680060-C22635BD-C458-41E8-95B2-09D8833AA476Q28082939-65662D46-60BC-4ED9-B819-4596188302F9Q28235733-B7E86B78-9FBB-4A10-958F-BC0CD6297B77Q28255877-A40C437C-6B48-4B3D-BEE1-45FCD86D92CAQ28396399-0590FE4E-AC14-4FAB-8B30-04446D9E5A07Q28397866-8AC4394B-3CAD-4AA6-8927-25F9AE079E86Q28551448-167EA50E-5CA4-41DD-AE56-D8101E795C20Q28828356-60C2A27A-5D75-4C1A-A87B-B541CFD3E718Q30203249-7D3ED546-0DF4-438B-BB7C-F0FBE4D91EF2Q30238537-B4EFD26B-DF61-48C4-8607-A2AAF94A74E5Q30245073-5D4F05A1-41F6-4ED3-9D85-7D2E61000734Q30251949-428C3DEB-60F7-4633-8727-2301EB566E75Q30252022-E2DD89A4-A321-4FD2-B947-58DB3B7284D4Q30279239-2787B39C-1988-4127-A12C-07966DE1F43CQ30356113-E2EBC7E7-6CAB-4E19-96D8-D20C31D0F941Q30383481-6EA1DC60-4112-43F2-B239-EC38969CAA7AQ30531035-91724740-25FF-49AE-A6DC-FC88EBCE4E42Q33701830-C333E1D9-8F6E-4485-96BB-F0C47CB33ADE
P2860
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Postexposure protection of non ...... nce: a proof-of-concept study.
@ast
Postexposure protection of non ...... nce: a proof-of-concept study.
@en
Postexposure protection of non ...... nce: a proof-of-concept study.
@nl
type
label
Postexposure protection of non ...... nce: a proof-of-concept study.
@ast
Postexposure protection of non ...... nce: a proof-of-concept study.
@en
Postexposure protection of non ...... nce: a proof-of-concept study.
@nl
prefLabel
Postexposure protection of non ...... nce: a proof-of-concept study.
@ast
Postexposure protection of non ...... nce: a proof-of-concept study.
@en
Postexposure protection of non ...... nce: a proof-of-concept study.
@nl
P2093
P50
P1433
P1476
Postexposure protection of non ...... nce: a proof-of-concept study.
@en
P2093
Adam Judge
Amy C H Lee
Ian Maclachlan
Iran Tavakoli
Joan B Geisbert
Marjorie Robbins
Susan de Jong
Vandana Sood
P304
P356
10.1016/S0140-6736(10)60357-1
P407
P577
2010-05-01T00:00:00Z